Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 26, 2026British Journal of Pain

OnabotulinumtoxinA in refractory postherpetic neuralgia: a case report

View Full Paper
Ask AI
Bookmark
Share

Authors

DBDominic BertramGHGeorg HaberDRDina von Rohrscheidt

Discussion

Loading...

Member takes

Overview

Case report shows onabotulinumtoxinA effectively reduces pain in patients with refractory postherpetic neuralgia, suggesting a new treatment option.

Key Points

  • This report aims to evaluate the efficacy of onabotulinumtoxinA in treating refractory postherpetic neuralgia.
  • Single-blinded treatment with 200 IU onabotulinumtoxinA injected into thoracic postherpetic neuralgia area across 40 points.
  • One corner of the affected area injected with saline as a blinded comparison.
  • Follow-up treatment with an additional 100 IU onabotulinumtoxinA 24 days later.
  • Pain intensity decreased from 10/10 to 5/10 in the BoNT/A-treated area.
  • No noteworthy improvement in the saline-injection area.
  • Clinical effect sustained for approximately 3 months, with substantial pain reduction lasting nearly 1 year after repeated treatment.

Cite This Study

Bertram et al. (2026) studied this question.

synapsesocial.com/papers/6a65a84ed3aea3239cd78b77https://doi.org/10.1177/20494637261471112
View Full Paper
Ask AI
Bookmark
Share